The MAPK (RAS/RAF/MEK/ERK) signaling pathway is hyperactivated in AML patients, leading to leukemogenesis, leukemia progression, and chemo resistance [53–56]. The gene discussed is MAP2K7; the disease is acute myeloid leukemia.